
iBio initiates Phase I trial for weight loss antibody
iBio has received approval to initiate a first-in-human clinical trial for its long-acting monoclonal antibody IBIO-600 in Australia. The Phase I study is a randomised, double-blind, placebo-controlled, single ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight and obese adult… Read More











